GL1X · GenesisL1 explorer

MolNFT v1 · #128096 · protein

Crystal structure of USP7 in complex with the non-covalent inhibitor, FT671

5NGE · Ubiquitin carboxyl-terminal hydrolase 7: “Crystal structure of USP7 in complex with the non-covalent inhibitor, FT671”. X-ray diffraction, 1 ligand (8WK), 7 pockets (best druggability 0.71). MolNFT v1 #128096 on GenesisL1: 3D…

PDB
5NGE
Type
protein
Length
650 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ubiquitin carboxyl-terminal hydrolase 7
EC
3.4.19.12
UniProt
Q93009
Ligands
8WK
Pockets
7 · best druggability 0.71

Structure

x-ray diffraction · 2 distinct chains · 34% helix, 26% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AUbiquitin carboxyl-terminal hydrolase 7 (EC 3.4.19.12)protein33735% helix, 27% strandQ93009
BUbiquitin carboxyl-terminal hydrolase 7 (EC 3.4.19.12)protein31333% helix, 24% strandQ93009

Ligands and binding sites

  • 8WK · 5-[[1-[(3~{S})-4,4-bis(fluoranyl)-3-(3-fluoranylpyrazol-1-yl)butanoyl]-4-oxidanyl-piperidin-4-yl]methyl]-1-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-4-one · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11820.710.88228WK
21880.690.87248WK
38650.690.7575empty
41040.380.7519empty
51010.370.7416empty

Interfaces

1 interface between chains.

  • A–B · 158 Ų buried · 0 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 disulfide (disulfide).

Compared structures

  • 5NGE · Crystal structure of USP7 in complex with the non-covalent inhibitor, FT671 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.